e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS
MWN-AI** Summary
Tangram Therapeutics, formerly known as e-therapeutics, has officially relaunched as part of its ambitious strategic pivot towards RNA interference (RNAi) therapies, aiming for significant advancements in drug development. The London-based biotech company is gearing up for the submission of a Clinical Trial Application (CTA) for its lead program, TGM-312, targeting metabolic dysfunction-associated steatohepatitis (MASH), expected in the fourth quarter of 2025.
A key highlight of the relaunch is the introduction of LLibra OS, an advanced AI platform designed to enhance the discovery and evaluation of novel gene targets and small interfering RNA (siRNA) medicines. LLibra OS builds upon the foundation of its predecessor, HepNet, utilizing proprietary network analytics to model human disease biology. This platform's sophisticated architecture allows Tangram to integrate insights from diverse datasets to identify promising therapeutic targets and streamline siRNA development.
Tangram's pipeline includes not only TGM-312 but also TGM-148, which addresses bleeding disorders and is anticipated to enter clinical trials in mid-2026. By leveraging its proprietary GalOmic chemistry and the advanced capabilities of LLibra OS, Tangram Therapeutics seeks to differentiate itself from the crowded biopharma landscape by delivering first-in-class RNAi medicines that are substantiated by robust evidence.
CEO Ali Mortazavi emphasized that the company’s transformation signals a dedicated focus on combining expertise in AI, biology, and chemistry to identify and develop innovative medicines more efficiently. The metaphorical connection to the Tangram puzzle represents the synthesis of varied disciplines to create groundbreaking therapies. With a commitment to making smarter and earlier decisions in development, Tangram aims to significantly reduce risks while achieving meaningful impacts in addressing diverse diseases with high unmet needs.
MWN-AI** Analysis
Tangram Therapeutics' relaunch, former e-therapeutics, signifies a strategic pivot in the biotech sector, focusing on RNA interference (RNAi) medicine with the introduction of its next-generation AI platform, LLibra OS. This transition appears well-timed as it positions the company to address significant unmet medical needs, particularly in metabolic dysfunction-associated steatohepatitis (MASH) and bleeding disorders through its lead programs TGM-312 and TGM-148.
The rebranding reflects Tangram’s commitment to integrating advanced computational techniques with innovative RNAi therapies, which is critical in today's competitive biotech market. The expected regulatory submission of TGM-312 by Q4 2025 hints at a robust clinical pipeline, potentially enabling early-stage investors to tap into promising returns as Tangram moves towards its first clinical trials.
LLibra OS is a noteworthy advancement, leveraging AI to streamline drug discovery and target identification processes. Its ability to analyze and synthesize insights from varied datasets enhances Tangram's capability to design effective siRNA treatments while reducing developmental risks. Such innovation could differentiate Tangram from its peers, who often rely on more traditional drug discovery methods.
From an investment perspective, Tangram Therapeutics presents a compelling opportunity, particularly with its unique positioning in the RNAi market. Analyst projections should take into account the anticipated clinical data that will emerge from the forthcoming trials, as well as the strategic implications of a successful market entry for TGM-312. Furthermore, ongoing developments in AI and RNAi medicine will likely bolster the company’s valuation in the near term, making it an attractive proposition for investors looking to capitalize on biotech innovations.
In summary, Tangram Therapeutics’ dual focus on pioneering RNAi therapies and cutting-edge AI platforms establishes a potentially profitable investment landscape, with significant implications as the company progresses towards regulatory submissions and clinical validations. Investors should monitor forthcoming milestones closely, as they will be crucial in determining market confidence and stock performance.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Relaunch marks pivotal next step in the company’s growth, in anticipation of first CTA submission in Q4 2025.
Introducing LLibra OS, a next-generation AI platform that accelerates discovery and evaluation of differentiated gene targets and siRNA design.
LONDON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Tangram Therapeutics (formerly e-therapeutics), a company committed to uniting computation and RNAi to make better medicines faster, today announced its corporate relaunch. Tangram Therapeutics is inspired by a geometric puzzle, in which differently shaped pieces can be arranged in countless ways to create something greater. Similarly, the Company brings together biological insights, AI, proprietary chemistry, and its people in a focused effort to accelerate the discovery and development of innovative RNAi medicines that transform lives.
Today’s relaunch reflects the progress made since the Company’s pivot to RNA interference medicines. Since then, Tangram Therapeutics has advanced a broad therapeutic pipeline of differentiated GalOmic medicines, powered by its proprietary computational and data-driven approaches. The Company’s lead program, TGM-312 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), is rapidly advancing toward a CTA submission in Q4 2025. As part of its broader pipeline, Tangram is also progressing TGM-148 for the treatment of bleeding disorders through IND-enabling studies, with a regulatory submission for clinical entry planned during 2026. Tangram’s pipeline of first-in-class RNAi medicines highlights both the power of its GalOmic chemistry platform and its ability to discover differentiated therapeutic approaches.
In addition to its relaunch, the Company has unveiled LLibra OS, its next-generation applied AI platform with a modular, multi-agent infrastructure that can continually evolve with the latest advances in AI. LLibra OS is built on the foundations of Tangram’s precursor computational platform HepNet, which was anchored on proprietary network analytics applied to model human disease biology. LLibra OS unifies insights from disparate datasets and proprietary analytical capabilities to enable the identification of novel targets, the evaluation of their therapeutic potential and developability, and the predictive design of GalOmic siRNA medicines. LLibra OS’s co-scientist functionality also supports Tangram’s scientific teams more broadly to increase efficiency and innovation across all research and development activities.
By evolving its proven computational expertise into a more autonomous and integrated AI system, Tangram Therapeutics aims to make smarter decisions earlier in development, to systematically reduce risk and accelerate development of its GalOmic medicines. This advancement reflects the Company’s broader transformation into a data-driven RNAi leader, uniting advanced AI with proprietary chemistry to deliver differentiated medicines.
“Our relaunch today as Tangram Therapeutics represents far more than a new name,” said Ali Mortazavi, Chief Executive Officer of Tangram Therapeutics. “It reflects the company we have become — one that unites proven expertise in AI, biology, and chemistry with a clear focus on developing RNAi medicines. By combining these elements, we are better equipped to identify targets, design effective medicines, and accelerate their path to patients. This bold strategy allows us to diverge from the crowded therapeutic hypotheses being extensively pursued in biopharma and offer differentiated options to patients and carers.”
“Like the eponymous puzzle, Tangram Therapeutics is about connection, perspective, and innovation,” added Alan Whitmore, Chief Scientific Officer. “This extends to LLibra OS, which enables us to make non-obvious connections between diverse pieces of information across widely disparate domains, to identify and evaluate novel targets. This approach ensures that the first-on-target and first-in-class programs in our pipeline are backed by robust evidence and de-risked ahead of development.”
About Tangram Therapeutics
Tangram Therapeutics (formerly e-therapeutics) is a biotech company committed to uniting computation, RNAi, and unconventional thinking to make better medicines faster. We are advancing a pipeline of GalOmic RNAi medicines for a broad range of diseases with high unmet need. Our lead programs TGM-312 for MASH and TGM-148 for bleeding disorders are approaching the clinic, on track for regulatory submissions in Q4 2025 and mid-2026, respectively.
Tangram’s innovative medicines are enabled by GalOmic, our proprietary RNAi chemistry platform designed to selectively silence disease-driving genes in hepatocytes. Discovery is powered by LLibra OS, our next-generation AI platform with an agentic infrastructure. The unique combination of these platforms is the foundation of our Relentless Medicine Discovery. Faster, smarter development of RNAi medicines designed for real-world impact.
Learn more at www.tangramtx.com .
Media Contact
press@tangramtx.com
Investor Relations Contact
IR@tangramtx.com
FAQ**
How does Tangram Therapeutics plan to leverage its new LLibra OS platform to improve efficiencies in drug development compared to its previous computational strategies used under E-Therapeutics Plc ETXPF?
With the anticipated CTA submission for TGM-312 in Q4 2025, what key milestones does Tangram Therapeutics foresee as critical for maintaining investor confidence following its transition from E-Therapeutics Plc ETXPF?
How does Tangram’s GalOmic platform enhance the therapeutic potential of their RNAi medicines compared to traditional approaches previously employed under E-Therapeutics Plc ETXPF?
Can Tangram Therapeutics elaborate on how its mission as a data-driven RNAi leader will affect its competitive positioning against other biotech firms in the RNAi space that were also previously under E-Therapeutics Plc ETXPF?
**MWN-AI FAQ is based on asking OpenAI questions about E-Therapeutics Plc (OTC: ETXPF).
NASDAQ: ETXPF
ETXPF Trading
100.0% G/L:
$0.13 Last:
30 Volume:
$0 Open:
